Literature DB >> 16687166

Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice.

Zhi-fei Wang1, Li-li Tang, Han Yan, Yu-jun Wang, Xi-can Tang.   

Abstract

This study is to investigate the effects of huperzine A on memory deficits, neuronal damage and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice, as well as the potential downstream signaling pathway. Bilateral common carotid occlusion (BCCAo) combined with systemic hypotension induced severe memory deficits in a water maze task and neuronal degeneration in cerebral cortex and hippocampus in mice. Oral administration of huperzine A (0.2 mg/kg, once per day, started 2 days before surgery and lasted for 7 days after surgery) markedly attenuated the memory deficits and neuronal damage. Meanwhile, huperzine A significantly increased the mRNA and protein levels of NGF, BDNF and TGF-beta(1), and potentiated phosphorylation of MAPK/ERK 1/2 in both cerebral cortex and hippocampus compared with transient cerebral ischemia and reperfusion group. This study provides evidence for the protective effects of huperzine A against transient cerebral ischemia and reperfusion in mice, and suggests potentially important roles that neurotrophic factors might play in these effects. It also indicates that the MAPK/ERK pathway might be involved in the in vivo neurotrophic effects of huperzine A against transient cerebral ischemia and reperfusion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16687166     DOI: 10.1016/j.pbb.2006.03.027

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  28 in total

1.  The effects of huperzine A and IDRA 21 on visual recognition memory in young macaques.

Authors:  Ludise Malkova; Alan P Kozikowski; Karen Gale
Journal:  Neuropharmacology       Date:  2010-12-23       Impact factor: 5.250

2.  Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model.

Authors:  Chun-Yan Wang; Wei Zheng; Tao Wang; Jing-Wei Xie; Si-Ling Wang; Bao-Lu Zhao; Wei-Ping Teng; Zhan-You Wang
Journal:  Neuropsychopharmacology       Date:  2011-02-02       Impact factor: 7.853

Review 3.  Neurotrophic natural products: chemistry and biology.

Authors:  Jing Xu; Michelle H Lacoske; Emmanuel A Theodorakis
Journal:  Angew Chem Int Ed Engl       Date:  2013-12-18       Impact factor: 15.336

Review 4.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

Review 5.  Neurotrophin strategies for neuroprotection: are they sufficient?

Authors:  Joseph P Steiner; Avindra Nath
Journal:  J Neuroimmune Pharmacol       Date:  2014-03-08       Impact factor: 4.147

6.  Original Research: The expression of MMP2 and MMP9 in the hippocampus and cerebral cortex of newborn mice under maternal lead exposure.

Authors:  Ning Li; Xing Li; Li Li; Pingan Zhang; Mingwu Qiao; Qiuyan Zhao; Lianjun Song; Zengli Yu
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-02

7.  Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease.

Authors:  T Leyhe; Elke Stransky; G W Eschweiler; G Buchkremer; C Laske
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

Review 8.  BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases.

Authors:  Bai Lu; Guhan Nagappan; Xiaoming Guan; Pradeep J Nathan; Paul Wren
Journal:  Nat Rev Neurosci       Date:  2013-05-15       Impact factor: 34.870

Review 9.  Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.

Authors:  Juan Wang; Hai-Yan Zhang; Xi-Can Tang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

10.  Pharmacodynamic study of FS-0311: a novel highly potent, selective acetylcholinesterase inhibitor.

Authors:  Zhi Fei Wang; Jin Yan; Yan Fu; Xi Can Tang; Song Feng; Xu Chang He; Dong Lu Bai
Journal:  Cell Mol Neurobiol       Date:  2007-09-05       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.